Novo Nordisk announces major expansion of its diabetes care field force in the US

Novo Nordisk today announced plans to expand its diabetes care field force in the US, from around 1,200 to approximately 1,900 people. The expansion, which will take place during the first half of 2007, is designed to further strengthen Novo Nordisk's position in the US insulin market and to increase the company's 'share of voice' in the competitive market for diabetes products. The US insulin market is a key growth market for Novo Nordisk and with its more than 40% share of this market (measured in volume) Novo Nordisk is today the clear market leader. The field force expansion will support Novo Nordisk's complete portfolio of modern insulins (insulin analogues): Levemir®, a long-acting insulin, NovoLog® Mix 70/30 (NovoMix® 30 outside the US), a premixed formulation of rapid-acting and intermediate-acting insulin, and NovoLog® (NovoRapid® outside the US), a rapid-acting insulin. The expanded field force will make it possible to reach more primary care physicians and increase the frequency of visits to both primary care physicians and endocrinologists.

Source: Press-release Novo Nordisk 30.12.2006.

Read more at the Novo Nordisk homepage.